Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.

Related Keywords

Philadelphia ,Pennsylvania ,United States ,American ,Brentl Wood ,Susanm Obrien ,Anjalis Advani ,Aaront Gerds ,Jeraldp Radich ,Mark Litzow ,Janel Liesveld ,Matthew Wieduwilt ,Anna Moseley ,Harryp Erba ,Los Angeles ,Deepa Jeyakumar ,George Yaghmour ,Ceciliacs Yeung ,Kristen Odwyer ,Ehabl Atallah ,Megan Othus ,Elad Sharon ,Uc Irvine Medical Center ,Wilmot Cancer Institute ,Cancer Research Network ,Cleveland Clinic Cancer Institute ,National Cancer Institute ,Data Management Center ,University Of Washington ,Amgen Inc ,Dana Farber Cancer Institute ,University Of Oklahoma ,National Clinical Trials Network ,Cancer Therapy Evaluation Program ,American Society Of Hematology ,University Of Rochester ,Swog Cancer Research Network ,National Institutes Of Health ,Bristol Myers Squibb ,Memorial Sloan Kettering Cancer Center ,College Of Wisconsin ,Norris Comprehensive Cancer Center ,Duke University Medical Center ,Development Agreements ,Fred Hutchinson Cancer Center ,American Society ,Annual Meeting ,San Diego ,Kristeno Dwyer ,Research Network ,National Institutes ,Myers Squibb ,Cooperative Research ,Hospital Los Angeles ,Jae Park ,California San Diego Moores Cancer Center ,Medical Center ,Comprehensive Cancer Center ,Medical College ,Mayo Clinic ,Therapy Evaluation Program ,Duke University Medical ,Chemotherapy ,Mh ,Acute Lymphoblastic Leukemia ,Dancer ,Chromosome ,Clinical Trial ,Dasatinib ,Hematology ,Inase ,Leukemia ,Prednisone ,Research ,Tyrosine ,